RxDoctor Payments DataLook up a doctor →

Sonia Benn, MD

Hematology & Oncology · Southaven, MSNPI 1801825781

Payments from drug & device makers

$25,687in general payments, 2019–2025

Across 424 payments — averaging $60.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$12K
  • Daiichi Sankyo Inc.$5K
  • Novartis$2K
  • Gilead$877
  • Johnson & Johnson$855
  • Pfizer$384
  • plus $4K from 49 others

What the payments were for

  • Consulting fees$2,45010%
  • Speaking & faculty fees$13,29552%
  • Food & beverage$7,44929%
  • Education$4112%
  • Other$2,0828%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,687 in reported general payments places this provider in the 70th percentile of 57 hematology & oncology providers in Mississippi.

See all hematology & oncology providers in Mississippi

Medicare billing

Part B allowed, 2024
$6,334,800
Medicare patients
1,059
Services billed
236,541

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib98$1,524,983
VerzenioAbemaciclib83$1,121,096
KisqaliRibociclib Succinate30$316,276
EliquisApixaban58$36,649
Exemestane145$13,585
Letrozole605$10,046
Anastrozole748$9,133
Tamoxifen Citrate219$3,709
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen25$1,152
Gabapentin90$846
Prochlorperazine Maleate52$716
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen35$648
Oxybutynin Chloride28$589
Duloxetine Hcl54$435
Ondansetron OdtOndansetron22$411

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$384$1,561,631156 claims
Lilly USA, LLCVerzenio$291$1,121,09683 claims
NovartisKisqali$2,281$316,27630 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 57 hematology & oncology providers in Mississippi.

Other hematology & oncology in Southaven

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →